Trevi Therapeutics (TRVI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on the stock and has a $27.00 price target.
Debanjana Chatterjee has given his Buy rating due to a combination of factors surrounding Trevi Therapeutics. The anticipation of data from the Phase 2b CORAL trial, which is evaluating Haduvio for IPF-cough, is a significant driver. Positive outcomes from this trial could pave the way for a Phase 3 trial, potentially making Haduvio the first approved therapy for IPF-cough.
Furthermore, the interim analysis of the CORAL trial and the unexpectedly strong data from the RIVER trial in RCC set a high bar for success. The market is currently factoring in a 30% placebo-adjusted cough reduction, but Haduvio could exceed these expectations with a 35-45% effect size. This scenario could lead to a substantial increase in the stock price, making the risk-reward profile attractive ahead of the CORAL update.
In another report released on March 11, Leerink Partners also reiterated a Buy rating on the stock with a $11.00 price target.